No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 14.3x · 10Y median 15.3x · 46th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 19
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:06:12.505Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Coya Therapeutics, Inc. (COYA) stock was $4.91 as of Oct 6, 2026, 10:05 AM EDT, up 1.13% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -20.4% · 3-year avg +12.8%/yr
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs).
Biotechnology · Houston, TX
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.35
Revenue Est.
$110000.00
Last Quarter Results
EPS
$-0.28
vs Estimate
$-0.36
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1COYA | $115.06M | $4.91 | +1.13% | -20.40% | N/A | N/A | N/A |
| 2FHTX | $114.45M | $1.95 | -2.54% | -56.72% | -31.87% | N/A | vs COYA |
| 3LENZ | $116.25M | $3.71 | +3.28% | -92.54% | -35.49% | N/A | vs COYA |
| 4LUCD | $113.78M | $0.60 | +0.52% | -42.80% | N/A | N/A | vs COYA |
| 5GNLX | $116.36M | $2.60 | -0.19% | -41.42% | N/A | N/A | vs COYA |
| 6CRBU | $118.02M | $1.19 | +0.00% | -47.42% | -44.43% | N/A | vs COYA |
forward FY estimate
N/A
$221873.00
vs Estimate
$130000.00
Consensus Rating
Based on 7 analysts
Average Price Target
$15.21
+210.2% upside
Low
$12.00
Current
$4.91
High
$18.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.35 | $-0.34 | $-0.32 | 2 |
| Quarter ending Dec 2026 | $-0.40 | $-0.37 | $-0.34 | 2 |
| Quarter ending Mar 2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Quarter ending Jun 2027 | $-0.34 | $-0.34 | $-0.34 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.37 | $-1.33 | $-1.29 | 4 |
| FY 2027 | $-1.58 | $-1.43 | $-1.22 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $110000.00 | $110000.00 | $110000.00 | 7 |
| Quarter ending Dec 2026 | $660000.00 | $660000.00 | $660000.00 | 7 |
| Quarter ending Mar 2027 | $100000.00 | $100000.00 | $100000.00 | 3 |
| Quarter ending Jun 2027 | $3.43M | $3.43M | $3.43M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $728049.00 | $1.02M | $1.60M | 5 |
| FY 2027 | $814698.00 | $5.95M | $12.17M | 4 |
